相关实验视频

Updated: Jun 26, 2025

Transcranial Pulse Stimulation for Alzheimer's Patients

Transcranial Pulse Stimulation for Alzheimer's Patients

Published on: April 4, 2025

在轻度至中度阿尔茨海默氏症中p75神经热素受体调节:一个随机的,安慰剂控制的2a期试验

Hayley R C Shanks^1,2,3, Kewei Chen^4,5,6, Eric M Reiman^4,5,7,8,9

¹Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada. hayley.r.shanks@gmail.com.

Nature medicine

|May 17, 2024

概括

LM11A-31,一种针对p75神经质受体 (p75NTR) 的新药,在2a期试验中显示出安全性并减缓了阿尔茨海默病 (AD) 的进展. 认知功能没有显著改善,但生物标志物数据表明治疗潜力.

科学领域:

神经科学是一个神经科学.
药理学药理学是指药理学的学科.
老年学是一门学科.

背景情况:

p75神经热素受体 (p75NTR) 信号与阿尔茨海默病 (AD) 神经退行有关.
临床前研究表明,LM11A-31可以减轻AD模型中的突触损失.

研究的目的:

评估LM11A-31在轻度至中度AD的安全性和耐受性.
探索药物对AD病理生理特征和认知衰退的影响.

主要方法:

一个26周的,随机的,安慰剂控制的,双盲的2a期试验.
242名患有轻度至中度AD的参与者每天两次接受安慰剂,200毫克或400毫克LM11A-31.
评估了安全性,耐受性,结构性MRI,FDG-PET,CSF生物标志物和认知测试.

主要成果:

该试验满足了其安全性和耐受性的主要终点.
在二次/探索性结局 (MRI,PET,CSF生物标志物) 中观察到显著的药物-安慰剂差异,表明AD进展减缓.
在LM11A-31治疗后,没有观察到认知测试的显著改善.

结论:

在患有轻度至中度AD的个体中,LM11A-31是安全的,并且耐受性良好.
这种药物在减缓AD病理生理进展方面具有潜力,这是生物标志物数据表明的.
需要在更大,更长时间的临床试验中进行进一步的调查.

更多相关视频

Using Enzyme-based Biosensors to Measure Tonic and Phasic Glutamate in Alzheimer's Mouse Models

Using Enzyme-based Biosensors to Measure Tonic and Phasic Glutamate in Alzheimer's Mouse Models

Published on: May 3, 2017

A Pilot Study on the Repetitive Transcranial Magnetic Stimulation of Aβ and Tau Levels in Rhesus Monkey Cerebrospinal Fluid

A Pilot Study on the Repetitive Transcranial Magnetic Stimulation of Aβ and Tau Levels in Rhesus Monkey Cerebrospinal Fluid

Published on: September 3, 2021

相关概念视频

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

Neural Regulation

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.